Seres Therapeutics Presents Preclinical Data At Digestive Disease Week (DDW) 2026 Supporting SER-603, A Next-Generation Cultivated Live Biotherapeutic Candidate, For Inflammatory Bowel Disease

(MENAFN - GlobeNewsWire - Nasdaq) Data highlight both SER-603's rational design that targets microbial functions linked to mucosal healing and gastrointestinal inflammation in IBD, as well as the ...